[ad_1]
Hanmi Pharmaceutical is reportedly exploring the potential for a global licensing deal for its new weight problems drug candidates.
Yeo No-rae, an analyst at Hyundai Motor Securities, mentioned on Jan. 23 that efinopegdutide, a remedy for metabolic dysfunction-associated steatohepatitis (MASH) led by accomplice U.S.-based Merck & Co. (MSD), accomplished its Part 2b clinicaltrial in December final 12 months, with outcomes anticipated to be offered at a medical convention within the first half of this 12 months. He famous that whereas the absence of feedback from MSD on the latest J.P. Morgan Healthcare Convention had weighed on the inventory, this was doubtless because of the double-blind nature of the trial, that means even MSD doesn’t but have entry to the information.
“The MASH triple-agonist efocifegtrutide is predicted to launch international Part 2b leads to the second half of this 12 months, whereas the weight problems remedy efpeglenatide is scheduled for launch throughout the identical interval,” Yeo mentioned. “Efpeglenatide has demonstrated significant weight-loss efficacy and a superior security profile, and is predicted to be priced decrease than competing medicine akin to Wegovy and Mounjaro. Backed by worth competitiveness and a steady provide from the Pyeongtaek Bio Plant, the corporate goals to achieve 100 billion received in gross sales inside one 12 months of launch.”
Yeo additional projected that “medical improvement for weight problems and MASH pipelines is progressing largely as deliberate,” including that “licensing-out alternatives within the weight problems market stay on the desk.” Hanmi Pharmaceutical can also be pushing to license out HM17321, a first-in-class weight problems drug designed to extend muscle mass. Not like current glucagon-like peptide-1 (GLP-1) therapies, it is a UCN2 analog concentrating on the CRF2 receptor.
Individually, Yeo forecast Hanmi Pharmaceutical’s 2025 consolidated income at 425.7billion received, up 21.1% 12 months on 12 months, with working revenue anticipated to surge 128.6% to 69.6 billion received. He attributed the robust outlook to elevated gross sales of respiratory pharmaceuticals akin to Hanmi Flu amid a extreme influenza season, increased royalty revenue from U.S. gross sales of neutropenia drug Rolvedon, and income from supplying medical trial supplies to companions.
[ad_2]
